RT Journal Article
SR Electronic
T1 Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.20248149
DO 10.1101/2021.01.08.20248149
A1 Ader, Florence
A1 Peiffer-Smadja, Nathan
A1 Poissy, Julien
A1 Bouscambert-Duchamp, Maude
A1 Belhadi, Drifa
A1 Diallo, Alpha
A1 Delmas, Christelle
A1 Saillard, Juliette
A1 Dechanet, Aline
A1 Mercier, Noémie
A1 Dupont, Axelle
A1 Alfaiate, Toni
A1 Lescure, François-Xavier
A1 Raffi, François
A1 Goehringer, François
A1 Kimmoun, Antoine
A1 Jaureguiberry, Stéphane
A1 Reignier, Jean
A1 Nseir, Saad
A1 Danion, François
A1 Clere-Jehl, Raphael
A1 Bouiller, Kévin
A1 Navellou, Jean-Christophe
A1 Tolsma, Violaine
A1 Cabie, André
A1 Dubost, Clément
A1 Courjon, Johan
A1 Leroy, Sylvie
A1 Mootien, Joy
A1 Gaci, Rostane
A1 Mourvillier, Bruno
A1 Faure, Emmanuel
A1 Pourcher, Valérie
A1 Gallien, Sébastien
A1 Launay, Odile
A1 Lacombe, Karine
A1 Lanoix, Jean-Philippe
A1 Makinson, Alain
A1 Martin-Blondel, Guillaume
A1 Bouadma, Lila
A1 Botelho-Nevers, Elisabeth
A1 Gagneux-Brunon, Amandine
A1 Epaulard, Olivier
A1 Piroth, Lionel
A1 Wallet, Florent
A1 Richard, Jean-Christophe
A1 Reuter, Jean
A1 Staub, Thérèse
A1 Hites, Maya
A1 Noret, Marion
A1 Andrejak, Claire
A1 Peytavin, Gilles
A1 Lina, Bruno
A1 Costagliola, Dominique
A1 Yazdanpanah, Yazdan
A1 Burdet, Charles
A1 Mentre, France
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/01/09/2021.01.08.20248149.abstract
AB Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking.Objective To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a, hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in COVID-19 inpatients.Design Open-label, randomized, adaptive, controlled trial.Setting Multi-center trial with patients from France.Participants 583 COVID-19 inpatients requiring oxygen and/or ventilatory supportIntervention Standard of care (SoC, control), SoC plus lopinavir/ritonavir (400 mg lopinavir and 100 mg ritonavir every 12h for 14 days), SoC plus lopinavir/ritonavir plus IFN-ß-1a (44 μg of subcutaneous IFN-ß-1a on days 1, 3, and 6), SoC plus hydroxychloroquine (400 mg twice on day 1 then 400 mg once daily for 9 days) or SoC plus remdesivir (200 mg intravenously on day 1 then 100 mg once-daily for hospitalization duration or 10 days).Measurements The primary outcome was the clinical status at day 15, measured by the WHO 7-point ordinal scale. Secondary outcomes included SARS-CoV-2 quantification in respiratory specimens and safety analyses.Results Adjusted Odds Ratio (aOR) for the WHO 7-point ordinal scale were not in favor of investigational treatments: lopinavir/ritonavir versus control, aOR 0.83, 95%CI, 0.55 to 1.26, P=0.39; lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69, 95%CI, 0.45 to 1.04, P=0.08; hydroxychloroquine versus control, aOR 0.93, 95%CI, 0.62 to 1.41, P=0.75. No significant effect on SARS-CoV-2 RNA clearance in respiratory tract was evidenced. Lopinavir/ritonavir-containing treatments were significantly associated with more SAE.Limitations Not a placebo-controlled, no anti-inflammatory agents tested.Conclusion No improvement of the clinical status at day 15 nor SARS-CoV-2 RNA clearance in respiratory tract specimens by studied drugs. This comforts the recent Solidarity findings.Registration NCT04315948.Funding PHRC 2020, Dim OneHealth, REACTingCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04315948Funding StatementThe trial was funded by grants from Programme Hospitalier de Recherche Clinique (PHRC-20-0351) (Ministry of Health), from the DIM One Health Ile-de-France (R20117HD) and from REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases. The funding sources had no role in the analysis of the data nor in the decision of publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethics Committee (CPP Ile-de-France-III, approval #20.03.06.51744).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonnable request to the corresponding author